Every 424B that MetaVia Inc. (MTVA) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow MTVA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MTVA filings page.
Metavia Inc. registers the offer and sale of up to an aggregate offering price of $4,000,000 of its common stock under an At-The-Market sales agreement with Ladenburg Thalmann & Co. Inc.
The supplement increases the prior ATM capacity from $2,300,000. Through the date of the supplement the company sold $2,126,303 of common stock under the Sales Agreement. The filing cites a last reported sales price of $1.45 per share on July 1, 2026 and an aggregate market value of shares held by non-affiliates of $18,438,694 based on 4,789,271 shares at $3.85 per share on May 22, 2026.
MetaVia Inc. registered for resale up to 936,846 shares of common stock by selling securityholders, including 231,320 PIPE Shares, up to 693,962 shares issuable on exercise of 2024 Series B Warrants and up to 11,564 shares issuable on Placement Agent Warrants. The resale registration was required under registration rights agreements related to private placements.
The Company will not receive proceeds from resale by the selling holders, but would receive proceeds if the Warrants are exercised for cash — up to approximately $30.6 million assuming full cash exercise. Shares outstanding were 5,090,936 as of March 20, 2026.
MetaVia Inc. is offering 614,840 Class A Units and 1,998,704 Class B Units, plus 9,839,336 shares of common stock issuable upon exercise of pre-funded and common warrants. Each Class A Unit includes one common share and 1.5 Series C and 1.5 Series D common warrants at a combined price of $3.10; each Class B Unit replaces the share with a pre-funded warrant at $3.099. Gross proceeds are expected to be about $8.10 million, with estimated net proceeds of approximately $6.6 million before any warrant exercises.
MetaVia plans to use the cash primarily for working capital and to continue developing DA-1726 for obesity. The company is a clinical-stage biotech also advancing Vanoglipel (DA-1241) for MASH and Type 2 diabetes and recently reported positive Phase 1 and Phase 2a topline data. MetaVia reports preliminary year-end 2025 cash of about $10.3 million with no debt and expects current resources plus this offering to fund operations into the third quarter of 2026, but it has a substantial accumulated deficit and a going concern warning.
MetaVia Inc. launched an at-the-market offering of up to $2,300,000 of Common Stock, to be sold from time to time through Ladenburg Thalmann under a Sales Agreement as “at the market offerings” under Rule 415.
Ladenburg will act as sales agent or principal and receive a commission of up to 3.0% of the aggregate gross sales price. MetaVia intends to use any net proceeds for working capital and general corporate purposes. Under General Instruction I.B.6 of Form S-3, the company notes a public float of $2,329,870 and is limited to selling no more than one‑third of its public float in any 12‑month period while below $75 million.
Shares outstanding were 24,214,788 as of September 30, 2025. The company illustrates that, assuming sales of 2,300,000 shares at $1.00, shares outstanding could reach 26,514,788 and new investors would see illustrative dilution of $0.69 per share. The filing also highlights Nasdaq minimum bid price deficiency risk and prior stockholder approval for a potential reverse split.